Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16alpha-hydroxyestrone ratio in premenopausal and postmenopausal women. Export

@article{citeulike:4958303, abstract = {Experimental and clinical evidence suggests that 16alpha-hydroxylated estrogen metabolites, biologically strong estrogens, are associated with breast cancer risk, while 2-hydroxylated metabolites, with lower estrogenic activity, are weakly related to this disease. This study analyzes the association of breast cancer risk with estrogen metabolism, expressed as the ratio of 2-hydroxyestrone to 16alpha-hydroxyestrone, in a prospective nested case-control study. Between 1987 and 1992, 10,786 women (ages 35-69 years) were recruited to a prospective study on breast cancer in Italy, the "Hormones and Diet in the Etiology of Breast Cancer" (ORDET) study. Women with a history of cancer and women on hormone therapy were excluded at baseline. At recruitment, overnight urine was collected from all participants and stored at -80 degrees C. After an average of 5.5 years of follow-up, 144 breast cancer cases and four matched controls for each case were identified among the participants of the cohort. Among premenopausal women, a higher ratio of 2-hydroxyestrone to 16alpha-hydroxyestrone at baseline was associated with a reduced risk of breast cancer: women in the highest quintile of the ratio had an adjusted odds ratio (OR) for breast cancer of 0.58 [95\% confidence interval (CI) = 0.25-1.34]. The corresponding adjusted OR in postmenopausal women was 1.29 (95\% CI = 0.53-3.10). Results of this prospective study support the hypothesis that the estrogen metabolism pathway favoring 2-hydroxylation over 16alpha-hydroxylation is associated with a reduced risk of invasive breast cancer risk in premenopausal women.}, author = {Muti, P. and Bradlow, H. L. and Micheli, A. and Krogh, V. and Freudenheim, J. L. and Sch\"{u}nemann, H. J. and Stanulla, M. and Yang, J. and Sepkovic, D. W. and Trevisan, M. and Berrino, F.}, citeulike-article-id = {4958303}, citeulike-linkout-0 = {http://view.ncbi.nlm.nih.gov/pubmed/11055622}, citeulike-linkout-1 = {http://www.hubmed.org/display.cgi?uids=11055622}, issn = {1044-3983}, journal = {Epidemiology (Cambridge, Mass.)}, keywords = {breast, cancer, estrogen, postmenopausal, premenopausal, thelist}, month = {November}, number = {6}, pages = {635--640}, posted-at = {2009-06-25 16:10:13}, priority = {2}, title = {Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16alpha-hydroxyestrone ratio in premenopausal and postmenopausal women.}, url = {http://view.ncbi.nlm.nih.gov/pubmed/11055622}, volume = {11}, year = {2000} }

TY - JOUR ID - citeulike:4958303 L3 - citeulike-article-id:4958303 N2 - Experimental and clinical evidence suggests that 16alpha-hydroxylated estrogen metabolites, biologically strong estrogens, are associated with breast cancer risk, while 2-hydroxylated metabolites, with lower estrogenic activity, are weakly related to this disease. This study analyzes the association of breast cancer risk with estrogen metabolism, expressed as the ratio of 2-hydroxyestrone to 16alpha-hydroxyestrone, in a prospective nested case-control study. Between 1987 and 1992, 10,786 women (ages 35-69 years) were recruited to a prospective study on breast cancer in Italy, the "Hormones and Diet in the Etiology of Breast Cancer" (ORDET) study. Women with a history of cancer and women on hormone therapy were excluded at baseline. At recruitment, overnight urine was collected from all participants and stored at -80 degrees C. After an average of 5.5 years of follow-up, 144 breast cancer cases and four matched controls for each case were identified among the participants of the cohort. Among premenopausal women, a higher ratio of 2-hydroxyestrone to 16alpha-hydroxyestrone at baseline was associated with a reduced risk of breast cancer: women in the highest quintile of the ratio had an adjusted odds ratio (OR) for breast cancer of 0.58 [95% confidence interval (CI) = 0.25-1.34]. The corresponding adjusted OR in postmenopausal women was 1.29 (95% CI = 0.53-3.10). Results of this prospective study support the hypothesis that the estrogen metabolism pathway favoring 2-hydroxylation over 16alpha-hydroxylation is associated with a reduced risk of invasive breast cancer risk in premenopausal women. IS - 6 JF - Epidemiology (Cambridge, Mass.) SN - 1044-3983 EP - 640 TI - Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16alpha-hydroxyestrone ratio in premenopausal and postmenopausal women. VL - 11 SP - 635 KW - breast KW - cancer KW - estrogen KW - postmenopausal KW - premenopausal KW - thelist AU - Muti, P AU - Bradlow, HL AU - Micheli, A AU - Krogh, V AU - Freudenheim, JL AU - Schünemann, HJ AU - Stanulla, M AU - Yang, J AU - Sepkovic, DW AU - Trevisan, M AU - Berrino, F PY - 2000/11// UR - http://view.ncbi.nlm.nih.gov/pubmed/11055622 ER -